Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Real World Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male patients diagnosed with moderate to severe hemophilia A (≤ 5% FVIII:C (Factor VIII Coagulant activity))~* Any age~* ≥ 50 exposure days (EDs) to any FVIII product~* Patients with or without history of inhibitors~  * Patient with previous history of inhibitors, with at least 2 consecutive negative inhibitor tests and on standard prophylaxis therapy for at least 1 year prior to study entry~ * No current evidence of FVIII inhibitor or clinical suspicion of FVIII inhibitor~    * Evidence of FVIII inhibitor as measured by the Nijmegen-modified Bethesda assay \[\<0.6 Bethesda units (BU/mL)\] or Bethesda assay \[\< 1.0 BU/mL\] in 2 on consecutives samples~   * Documented or clinical suspicion of shortened FVIII half-life (\< 6 hrs)~* Currently on or plan to start prophylaxis therapy with KOVALTRY~* Written informed consent~Exclusion Criteria:~* Patients participating in an investigational program with interventions outside of routine clinical practice~* Patients with an additional diagnosis of any bleeding/coagulation disorder other than hemophilia A~* Patients on Immune Tolerance Induction (ITI) treatment at the time of enrollment

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BAY81-8973 (Type: None): Previously treated patients receiving IV infusion of KOVALTRY for routine prophylaxis

Based on this trial design, predict the completion outcome and termination type (if applicable).